[Prevalence of Clostridium difficile in the gastrointestinal tract of hospitalized children under two years of age].
The aim of this study was to determine prevalence of C. difficile in the gastrointestinal tract of hospitalized children under two years of age and a comparison of phenotypic and genotypic features. Hundred and seventy-eight samples collected from the faecal samples of children aged 2 months to 2 years, hospitalized in 2003-2006 were examined for the presence of toxin A/B of C. difficile. Toxigenicity of strains was confirmed using PCR. Susceptibility to antimicrobials was determined using E-test. The percentage of children infected with C. difficile was 68.6%. Toxigenic of C. difficile strains A+B+CDT- accounted for 35%, A-B+CDT- 10%, and 5% were strains of A+B+CDT+. 50% of the cultivated strains were non-toxigenic. The percentage of strains resistant to erythromycin and clindamycin was respectively 52% and 42%. Resistance to ciprofloxacin was widespread concern 98% of strains, and the moxifloxacin and gatifloxacin was 8%. The percentage of resistant strains to imipenem was 50%. All tested strains were susceptible to metronidazole and vancomycin.
Wultańska
Dorota
D
Katedra i Zakład Mikrobiologii Lekarskiej WUM w Warszawie.
Obuch-Woszczatyński
Piotr
P
Banaszkiewicz
Aleksandra
A
Radzikowski
Andrzej
A
Pituch
Hanna
H
Młynarczyk
Grazyna
G
D001372:Aza Compounds / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D002981:Clindamycin / Q000494:pharmacology; D016360:Clostridioides difficile / Q000145:classification / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D024901:Drug Resistance, Multiple, Bacterial; D004917:Erythromycin / Q000494:pharmacology; D005243:Feces / Q000382:microbiology*; D005260:Female; D024841:Fluoroquinolones / Q000494:pharmacology; D041981:Gastrointestinal Tract / Q000382:microbiology*; D000077734:Gatifloxacin; D005838:Genotype; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008795:Metronidazole / Q000494:pharmacology; D000077266:Moxifloxacin; D010641:Phenotype; D011804:Quinolines / Q000494:pharmacology; D013045:Species Specificity; D014640:Vancomycin / Q000494:pharmacology
D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D008795:Metronidazole; D002981:Clindamycin; D002939:Ciprofloxacin; D004917:Erythromycin; D014640:Vancomycin; D000077734:Gatifloxacin; D000077266:Moxifloxacin